Full Press Release Details
Regulated information
IRVINE, CA, and LIEGE, BELGIUM, July 9, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, announced today that it received the following notifications of significant shareholdings, in accordance with the Belgian Act of May 2, 2007 on the disclosure of significant shareholdings in listed companies, as a result of the capital increase completed on June 25, 2013.
The shareholder notifications received following the completion of the capital increase are:
Shareholdings after actively crossing the transparency threshold:
Biovest Comm.VA., the investment vehicle of Rudi Mariën, has informed MDxHealth that its participation in MDxHealth crossed the threshold of 15% of the outstanding shares on June 25, 2013. Biovest Comm.VA. now owns 17.97% of the outstanding shares of MDxHealth.
Valiance Asset Management Ltd has informed MDxHealth that its participation in MDxHealth, through the different funds that it manages, crossed the threshold of 15% of the outstanding shares on June 25, 2013. Valiance Asset Management Ltd now controls 18.88% of the voting rights attached to the outstanding shares of MDxHealth.
Petercam NV has informed MDxHealth that its participation in MDxHealth, through the different funds that it manages, crossed the threshold of 3% of the outstanding shares on June 25, 2013. Petercam NV now controls 4.41% of the voting rights attached to the outstanding shares of MDxHealth.
Life Sciences Partners Fund II BV has informed MDxHealth that its participation in MDxHealth fell below the minimum statutory threshold of 3% of the outstanding shares on June 25, 2013.
ING Group NV has informed MDxHealth that its participation in MDxHealth fell below the minimum statutory threshold of 3% of the outstanding shares on June 25, 2013.
Shareholdings after passively crossing the transparency threshold:
IDInvest Partners has informed MDxHealth that its participation in MDxHealth fell below the minimum statutory threshold of 3% of the outstanding shares on June 25, 2013.
As per July 9, 2013, following the recent capital increase, MDxHealth had EUR 24,427,340.34 in cash and cash equivalents.
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The Company's first commercial product, ConfirmMDxTM for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth's website at www.mdxhealth.com.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
Attachments
To access the PDF version, please click here...